Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Followed by Imatinib in Newly Diagnosed CML
NCT03193281Phase 2Active, not recruiting
- Sponsor
- The University of Auckland
- Start
- Jul 2017
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, imatinib in chronic myeloid leukemia (CML), sponsored by The University of Auckland. Started Jul 2017; status: active, not recruiting.
02
Drugs
dasatinibimatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03193281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193281.